Quarterly report pursuant to Section 13 or 15(d)

7. Stockholders' Equity (Details Narrative)

v3.5.0.2
7. Stockholders' Equity (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Reverse stock split     On May 16, 2016, our board of directors approved a reduction, on a 1 for 33 basis    
IPR&D expense $ 39,500,000 $ 0 $ 39,500,000 $ 0  
Asset Purchase Agreement [Member]          
Stock issued with APA, shares issued         3,380,000
Stock available for issuance     3,045,455    
Warrant issues, common shares available for purchase 350,000   350,000    
Warrant term     5 years    
Date exercisable     Mar. 31, 2016    
Risk free interest rate     1.42%    
Expected volatility     135.00%    
Warrant fair value at grant date $ 1,700,000   $ 1,700,000    
Debt discount $ 1,700,000   $ 1,700,000    
Asset Purchase Agreement [Member] | Dr. Genkin [Member]          
Stock issued with APA, shares issued         330,000
Asset Purchase Agreement [Member] | Mr. Surkhov [Member]          
Stock issued with APA, shares issued         330,000
Asset Purchase Agreement [Member] | Pharmsynthez [Member]          
Stock issued with APA, shares issued     3,050,000    
IPR&D expense     $ 39,500,000